United States Pledges Continued Health Support To Zimbabwe

The United States says it has provided more than US$2.2 billion in global health assistance to Zimbabwe since 2004, supporting life-saving interventions and bolstering the country’s healthcare system.

In a statement on Monday, the U.S. Embassy in Harare said it is working with Zimbabwe’s Ministry of Health and Child Care to introduce lenacapavir, a twice-yearly injectable drug that is 96% effective at preventing HIV infections. The statement reads:

“As we join the Ministry of Health and Child Care to introduce U.S.-developed lenacapavir, a twice-yearly injectable that is 96% effective in preventing HIV infections, we welcome continued collaboration to build Zimbabwean ownership of Zimbabwean health outcomes.

“The American people have provided $2.2 billion in global health assistance to Zimbabwe since 2004, saving lives and strengthening Zimbabwean health systems.

“Together we are building a healthier future, powered by American innovation and shared accountability.”

Lenacapavir, marketed as Sunlenca and Yeztugo, is a long‑acting antiretroviral drug hailed as a breakthrough in HIV prevention.

The World Health Organisation (WHO) recommends it as a twice‑yearly injectable for those at high risk, due to its strong protective effect.

In September 2025, Zimbabwe was chosen as one of just ten countries worldwide for the initial rollout of lenacapavir, developed by Gilead Sciences in partnership with the Global Fund.

By October, the U.S. Embassy in Harare confirmed Zimbabwe’s inclusion, describing it as a “major step toward ending new infections.”

A phased rollout began in January 2026, targeting 12 high‑priority districts and urban centres, including Harare, Bulawayo, Gweru, Masvingo, Mutare, and Chitungwiza.

Related:

Bulawayo’s Magwegwe And Pumula Flagged As New HIV Hotspots Traditional court orders woman to pay husband a beast over alleged HIV transmission